| Drug Name |
Bimatoprost |
| Drug ID |
BADD_D00274 |
| Description |
Bimatoprost, also known as Latisse or Lumigan, belongs to a group of drugs called prostamides, which are synthetic structural analogs of prostaglandin. Bimatoprost, marketed by Allergan, is administered in both the ophthalmic solution and implant form. It has the ability to reduce ocular hypotension, proving effective in conditions such as ocular hypertension and glaucoma.[L6877,L6892,L6898,L12069] Bimatoprost is also used to treat eyelash hypotrichosis, or sparse eyelash growth.[L6910] It was initially approved by the FDA in 2001 for ocular hypertension and later approved for hypothrichosis in 2008, as eyelash growth became a desirable adverse effect for patients using this drug.[L4894] |
| Indications and Usage |
Bimatoprost is used for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
These patients must be intolerant to other intraocular pressure lowering medications or inadequately responsive to other treatments.[L6877]
Bimatoprost is also indicated to treat eyelash hypotrichosis.[L6910] |
| Marketing Status |
approved; investigational |
| ATC Code |
S01EE03 |
| DrugBank ID |
DB00905
|
| KEGG ID |
D02724
|
| MeSH ID |
D000069580
|
| PubChem ID |
5311027
|
| TTD Drug ID |
D0Q2XF
|
| NDC Product Code |
73309-002; 73212-076; 50383-908; 70069-403; 72266-139; 0781-6206; 42385-030; 54893-0009; 55679-113; 42571-128; 0023-3616; 0023-9652; 62332-511; 65862-802; 70069-401; 24002-0021; 76397-016; 46708-511; 72266-241; 38779-3066; 51552-1618; 50383-912; 0023-3205; 60505-0583; 68083-296; 68083-439; 65129-1206; 72266-140; 12079-1067; 57741-3000; 68083-295; 68180-429; 61556-070; 68245-0004; 71052-276; 73309-022; 73377-230; 82187-1001; 62332-507; 54245-7036; 63190-0290; 65035-130; 65727-025; 82231-102; 70069-402; 40016-005 |
| UNII |
QXS94885MZ
|
| Synonyms |
Bimatoprost | Latisse | Lumigan | AGN 192024 | 192024, AGN |
